175 related articles for article (PubMed ID: 16478808)
1. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein AC; Gunter MJ; Lafata JE; Harrold L; Nelson WW; Platt R
Ann Pharmacother; 2006 Mar; 40(3):386-91. PubMed ID: 16478808
[TBL] [Abstract][Full Text] [Related]
2. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
3. Comment: frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
Wall GC; Krypel L
Ann Pharmacother; 2006; 40(7-8):1473-4; author reply 1474. PubMed ID: 16835310
[No Abstract] [Full Text] [Related]
4. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
5. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
[TBL] [Abstract][Full Text] [Related]
6. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
7. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
9. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
10. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate prescription of allopurinol in a teaching hospital.
Athisakul S; Wangkaew S; Louthrenoo W
J Med Assoc Thai; 2007 May; 90(5):889-94. PubMed ID: 17596042
[TBL] [Abstract][Full Text] [Related]
12. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.
Paisansinsup T; Breitenstein MK; Schousboe JT
J Clin Rheumatol; 2013 Jun; 19(4):180-6. PubMed ID: 23669799
[TBL] [Abstract][Full Text] [Related]
13. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
15. A review of inpatients with adverse drug reactions to allopurinol.
Khoo BP; Leow YH
Singapore Med J; 2000 Apr; 41(4):156-60. PubMed ID: 11063179
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
[TBL] [Abstract][Full Text] [Related]
17. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
18. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
19. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with recurrent hospital admissions for gout: a case-control study.
Hutton I; Gamble G; Gow P; Dalbeth N
J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]